Videos

Expert perspectives on the advent of bispecific antibody therapy in relapsed/refractory follicular lymphoma, centered on data and experience with several novel agents.

Shared insight on the development and use of CAR T-cell therapy in patients with multiply relapsed follicular lymphoma.

Switching to the paradigm of multiply relapsed follicular lymphoma, expert participants discuss the rationale behind and use of PI3k- and EZH2- targeted therapies.

Matthew Matasar, MD and Laurie Sehn, MD, share insight on available therapies for relapsed or refractory follicular lymphoma and reflect on factors that help in treatment selection.

Centering discussion on both symptomatic and asymptomatic disease, expert participants highlight cornerstone frontline therapies in follicular lymphoma.

A brief review of the role that PET imaging plays in staging follicular lymphoma and how it may inform treatment decisions.

Key opinion leaders in the management of follicular lymphoma share their perspective on risk stratification and staging strategies to inform treatment decisionmaking.

Opening their discussion on follicular lymphoma, experts Matthew Matasar, MD and Laurie Sehn, MD, reflect on its indolent nature as a subset of non-Hodgkin lymphoma.

Closing out their discussion on the management of myeloproliferative neoplasms, Rami S. Komrokji, MD, and Pankit Vachhani, MD, look toward the future treatment paradigm.

Sagar Lonial, MD, FACP, provides a look at an upcoming Virtual Tumor Board program on BCMA-directed therapies in relapsed/refractory multiple myeloma treatment.

Lajos Pusztai, MD, DPhil, discusses recent data from the phase 3 KEYNOTE-522 trial of patients with triple-negative breast cancer.

Fred Saad, MD, FRSC, discusses the findings of a biomarker analysis of the PROpel trial in patients with metastatic castration-resistant prostate cancer.

The panel reviews the first- and second-line treatment options for the patient in the presented case, before and after knowing her molecular testing results.

Michelle Shiller, DO, AP/CP, MGP, describes the process of tissue biopsy testing at her institution from start to finish, and Zosia Piotrowska, MD, explains the likelihood of targetable alterations in cases of mNSCLC in patients with no smoking history.

Gene G. Finley, MD, discusses some of the challenges seen when treating patients with small cell lung cancer.

Tycel Phillips, MD, discusses recent changes in the mantle cell lymphoma treatment landscape.

Closing out his discussion on the management of metastatic melanoma, expert oncologist Sajeve Thomas, MD, summarizes unmet needs and looks toward future evolutions in the treatment paradigm.

Comprehensive insight from an expert oncologist regarding the adverse event profile of immunotherapy (IO) agents and how these can be mitigated while treating patients with metastatic melanoma.

Following his review of first-line treatment options in the setting of metastatic melanoma, Sajeve Thomas, MD, considers how he would manage patients at disease progression.

Expert perspective on the optimal selection and use of first-line therapy in patients diagnosed with metastatic melanoma in the context of the current treatment paradigm.

Sajeve Thomas, MD, reflects on the RELATIVITY-047 trial combining relatlimab, a LAG-3 inhibitor, with nivolumab, a PD-1 inhibitor, in the first-line setting of unresectable or metastatic melanoma.

A comprehensive review of how the first-line treatment armamentarium in unresectable or metastatic melanoma has evolved over time.

Dr Paul Bunn briefly reviews key efficacy data from a pooled analyses of trilaciclib in chemotherapy induced myelosuppression and discusses strategies to manage neutropenia in patients receiving chemotherapy for extensive-stage small cell lung cancer (ES-SCLC).

Expert oncologist Sajeve Thomas, MD, reviews the diagnosis and first-line management of a patient who presents with metastatic melanoma.

Marcia S. Brose, MD, PhD, FASCO, discusses NTRK gene fusions and identifying patients with thyroid cancer.

Joel Neal, MD, PhD, presents the case of a 66-year-old woman with no smoking history and a diagnosis of EGFR exon 20 mutation-positive mNSCLC.

Closing out their discussion on the management of blastic plasmacytoid dendritic cell neoplasm, expert panelists look toward the future treatment paradigm.

Key opinion leaders provide a comprehensive review of agents under investigation, alone or in combination, in patients with myelofibrosis.

Shared insight on a number of novel therapies and treatment modalities being investigated in patients with blastic plasmacytoid dendritic cell neoplasm.

Zosia Piotrowska, MD, explains molecular testing methods that can discover molecular alterations in common biomarkers in patients with mNSCLC.